Last updated: 2026-09-09 09:50:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Karyopharm Therapeutics Inc. (KPTI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,74, with a market capitalization of $40,60M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,70 to $10,99. This page covers its latest market performance, valuation, price trends and company information.
$40,60M | |
$1,74 | |
$735,08 | |
$1,70 | |
$1,72 | |
607,00 | |
1,36M | |
-- | |
$10,99 | |
$1,70 | |
-- | |
-- |
Karyopharm Therapeutics Inc. (KPTI) is trading at $1,74 in pre-market trading as of 2026-09-09 09:12:00, up 0,87% ($0,02) from the previous close of $1,72
Pre-market trading shows how investors are pricing KPTI before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Karyopharm Therapeutics Inc. (KPTI) moved from $1,87 to $1,74, representing a decline of 7,22% ($0,14).
The stock traded between $1,70 and $2,14 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,17 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0,4%
KPTI is currently trading at $1,74, placing it 0,4% of the way from its 52-week low of $1,70 to its 52-week high of $10,99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 228 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Karyopharm Therapeutics Inc. (KPTI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.